NFE2L1 (Nuclear Factor Erythroid 2-Like 1), also known as Nrf1 (Nuclear factor erythroid 2-related factor 1), is a master transcriptional regulator of the antioxidant response and cellular proteostasis. As a member of the Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor family, NFE2L1 activates genes containing Antioxidant Response Elements (AREs) in their promoters, coordinating a comprehensive defense network against oxidative stress and maintaining protein homeostasis—processes critically implicated in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntington-disease). [1] [@sykiotis2010]
Gene Information
...
NFE2L1 — Nuclear Factor Erythroid 2-Like 1
Overview
NFE2L1 (Nuclear Factor Erythroid 2-Like 1), also known as Nrf1 (Nuclear factor erythroid 2-related factor 1), is a master transcriptional regulator of the antioxidant response and cellular proteostasis. As a member of the Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor family, NFE2L1 activates genes containing Antioxidant Response Elements (AREs) in their promoters, coordinating a comprehensive defense network against oxidative stress and maintaining protein homeostasis—processes critically implicated in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntington-disease). [1] [@sykiotis2010]
The NFE2L1 protein contains several key structural domains: [2]
N-terminal Transactivation Domain (TAD): Regulates transcriptional activity through interactions with coactivators
Cap'n'Collar (CNC) Region: Basic DNA-binding domain that recognizes ARE sequences
Leucine Zipper (Zip) Domain: Mediates dimerization with small Maf proteins
Neh (Nrf2-ECH) Domains: Six conserved regulatory domains that interact with various signaling proteins
C-terminal Regulatory Region: Contains a degron that controls protein stability
Molecular Functions
NFE2L1 functions as a transcriptional activator through the following mechanisms:
DNA Binding: Forms heterodimers with small Maf proteins (MAFF, MAFG, MAFK) and binds to Antioxidant Response Elements (ARE) with the consensus sequence 5'-TGACnnnGC-3'
Transcriptional Activation: Recruits coactivators including CBP/p300, BRG1, and various histone acetyltransferases
Target Gene Activation: Regulates over 200 genes involved in antioxidant defense, xenobiotic metabolism, and proteostasis [3]
NFE2L1 is widely expressed throughout the [central nervous system](/brain-regions/central-nervous-system), with highest expression in: [4]
Cerebral [Cortex](/brain-regions/cortex): Particularly layers 2-3 and 5-6, involved in higher cognitive functions
[Hippocampus](/brain-regions/hippocampus): High expression in [CA1](/cell-types/ca1-pyramidal-neurons), [CA3](/cell-types/ca3-pyramidal-neurons), and [dentate gyrus](/cell-types/dentate-gyrus-granule-cells)
[Basal Ganglia](/brain-regions/basal-ganglia): Moderate expression in [striatum](/brain-regions/striatum) and [globus pallidus](/brain-regions/globus-pallidus)
[Substantia Nigra](/brain-regions/substantia-nigra): High expression in dopaminergic [neurons](/entities/neurons)
[Cerebellum](/brain-regions/cerebellum): Purkinje cells and granule cell layer
Brainstem: Motor nuclei and reticular formation
Cell Type Specificity
Neurons: High expression in excitatory glutamatergic neurons and inhibitory GABAergic neurons
[Astrocytes](/cell-types/astrocytes): Moderate expression, increases in response to oxidative stress
[Microglia](/cell-types/microglia): Low baseline expression, strongly induced by neuroinflammation
[Oligodendrocytes](/cell-types/oligodendrocytes): Moderate expression, important for myelin maintenance
Disease Associations
Alzheimer's Disease
NFE2L1 plays a complex role in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis: [5]
[Amyloid-beta](/proteins/amyloid-beta) Toxicity: NFE2L1 activation protects against Aβ-induced oxidative stress and neuronal death. Studies show decreased NFE2L1 activity in AD brain tissue, contributing to vulnerability of neurons to oxidative damage.
[Tau](/proteins/tau) Pathology: NFE2L1 regulates genes that influence tau phosphorylation and aggregation. Dysregulation of NFE2L1 may exacerbate tau pathology through impaired proteostasis.
Neuroinflammation: NFE2L1 modulates microglial inflammatory responses. Its dysregulation contributes to chronic neuroinflammation in AD.
Therapeutic Potential: Pharmacologic activation of NFE2L1 (e.g., with CDDO-Me, bardoxolone-methyl) represents a therapeutic strategy for AD to boost endogenous antioxidant defenses. [6]
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), NFE2L1 is critically involved in:
Dopaminergic Neuron Protection: NFE2L1 activation protects [ventral midbrain dopamine neurons](/cell-types/ventral-midbrain-dopamine-neurons) from oxidative stress-induced death. The [substantia nigra pars compacta](/brain-regions/substantia-nigra) has particularly high oxidative stress burden.
[Alpha-synuclein](/proteins/alpha-synuclein) Pathogenesis: NFE2L1 regulates autophagy genes that clear α-synuclein aggregates. Impaired NFE2L1 function may contribute to [Lewy body](/diseases/lewy-body-disease) formation.
Mitochondrial Dysfunction: NFE2L1 target genes include mitochondrial quality control regulators. Its dysfunction exacerbates mitochondrial deficits in PD.
Neuroprotective Compounds: Sulforaphane and other NFE2L1 activators have shown promise in PD models. [7]
Amyotrophic Lateral Sclerosis (ALS)
In [ALS](/diseases/amyotrophic-lateral-sclerosis), NFE2L1 dysfunction contributes to disease pathogenesis: [8]
Motor Neuron Vulnerability: NFE2L1 activity is reduced in ALS motor neurons, making them more susceptible to oxidative damage.
Protein Aggregation: Impaired proteostasis due to NFE2L1 dysfunction may contribute to [TDP-43](/mechanisms/tdp-43-proteinopathy) and SOD1 aggregation.
Astrocyte Dysfunction: Astrocytic NFE2L1 dysregulation affects support functions for motor neurons.
Therapeutic Implications: NFE2L1-activating compounds are being investigated for ALS treatment.
Huntington's Disease
In [Huntington's disease](/diseases/huntington-disease):
Transcriptional Dysregulation: NFE2L1 function is impaired by mutant huntingtin through sequestration of transcription coactivators.
Mitochondrial Protection: NFE2L1 target genes protect against mitochondrial dysfunction in HD.
Frontotemporal Dementia (FTD)
TDP-43 Pathology: NFE2L1 dysfunction may contribute to TDP-43 aggregation in FTD.
Oxidative Stress: Increased oxidative stress in FTD brains associated with reduced NFE2L1 activity.
Signaling Regulation
Activation Pathways
NFE2L1 activity is regulated by multiple signaling pathways:
Oxidative Stress Sensing: [Reactive oxygen species](/entities/reactive-oxygen-species) (ROS) oxidize cysteine residues on NFE2L1, altering its conformation and transcriptional activity.
ER Stress Response: The [unfolded protein response (UPR)](/mechanisms/endoplasmic-reticulum-stress)))))))))) activates NFE2L1 through PERK and ATF6 signaling. [9]
Kinase Signaling: MAPK/ERK, PI3K/Akt, and PKC pathways phosphorylate NFE2L1, modulating its activity.
Proteasomal Regulation: NFE2L1 protein stability is regulated by the ubiquitin-proteasome system.
Negative Regulation
Keap1-mediated degradation: While Keap1 primarily regulates NFE2L2, it can also sequester NFE2L1.
Phosphorylation: [GSK-3β](/entities/gsk3-beta) phosphorylation can inhibit NFE2L1 transcriptional activity.
Acetylation: p300-mediated acetylation can alter NFE2L1 DNA binding and stability.
Therapeutic Implications
Pharmacologic Activation
Several compounds activate NFE2L1 and are being investigated for neurodegenerative diseases:
CDDO-Me (Bardoxolone Methyl): Potent NFE2L1 activator, in clinical trials for diabetic kidney disease, being explored for AD/PD.
Sulforaphane: Natural NFE2L1 activator from cruciferous vegetables, shown neuroprotective in animal models.
Dimethyl fumarate (Tecfidera): FDA-approved for multiple sclerosis, activates NFE2L1 pathway.
Oltipraz: Synthetic NFE2L1 activator investigated for neuroprotection.